[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

North America Liver Disease Treatment Market by Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, and Chemotherapy) and Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others): Opportunity Analysis and Industry Forecast, 2020–2027

September 2020 | 137 pages | ID: N76BA680EE7BEN
Allied Market Research

US$ 4,649.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5.2% from 2020 to 2027.

Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions. For instance, hepatitis B is a liver disease caused by a virus called hepatitis B virus (HBV). This condition is treated using antiviral drugs and can also be prevented by use of vaccines. Furthermore, other drugs that are used in treatment of hepatitis include immunoglobulin. Similarly, liver cancer is treated by using chemotherapy drugs and targeted therapy. In addition, some autoimmune liver related disorders are treated with the use of corticosteroids.

Furthermore, liver associated conditions also require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection. Thus, there are various types of liver treatments offered in the market such as anti-viral drugs, immunosuppressant drugs, vaccines, immunoglobulin, corticosteroid, targeted therapy, and chemotherapy drugs. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders.

The major factors that contribute toward growth of the North America liver disease treatment market include increase in alcohol consumption & use of illegal drugs and rise in prevalence of liver disease. Furthermore, it is also a primary cause for worsening of various liver conditions, which require treatment. For instance, consumption of large quantity of alcohol can lead to liver condition called alcoholic hepatitis, which, in turn, leads to liver inflammation that requires treatment. Furthermore, factors such as surge in geriatric population and increase in government and non-government awareness programs also boost growth of the North America liver disease treatment market. For instance, older patients who acquire hepatitis C infection are more likely to develop cirrhosis in the coming years, owing to accelerated fibrosis rate and decreased immunity.

However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C of drugs restrict growth of the North America liver disease treatment market. For instance, approval processes require a huge capital investment. Moreover, any new drug manufacturing company that tries to enter into the market is bound to abide by these regulations. Therefore, these procedures are time consuming, which extends the time for their approval and commercialization and restricts growth of the market. Conversely, presence of strong pipeline products offer a lucrative opportunity for the market growth.

The North America liver disease treatment market is segmented on the basis of treatment type, disease type, and country to provide a detailed assessment of the market. By treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. By disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others. By country, it is classified into the U.S., Canada, and Mexico.Major players operating in the market include, Astellas Pharma Inc., Mylan N.V., AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Eli Lilly and Company, Pfizer Inc., Dynavax Technologies, Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).

KEY BENEFITS FOR STAKEHOLDERS
          • This report entails a detailed quantitative analysis along with the current global North America liver disease treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
          • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
  • By Treatment Type
    • Antiviral Drugs
    • Immunosuppressants
    • Vaccines
    • Immunoglobulins
    • Corticosteroids
    • Targeted Therapy
    • Chemotherapy
  • By Disease Type
    • Hepatits
    • Autoimmune Diseases
    • Ischemic Stroke
    • Stenosis
    • Others
  • By Country
      • U.S.
      • Canada
      • Mexico
  • List of key players profiled in the report:
  • Astellas Pharma Inc.
  • Mylan
  • AbbVie Inc.
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Eli Lilly and Company
  • Dynavax Technologies
  • Pfizer Inc.
  • Gilead Sciences, Inc.,
  • Bristol Myers Squibb
  • Emergent BioSolutions (Cangene bioPharma)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Sanofi
  • F. Hoffmann-La Roche AG
  • Novartis AG
CHAPTER 1: INTRODUCTION

1.1.Report description
1.2.Key market segments
  1.2.1.List of key players profiled in the report
1.3.Research methodology
  1.3.1.Primary research
  1.3.2.Secondary research
  1.3.3.Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings
  3.2.1.Top Winning Strategies
  3.2.2.Top investment pockets
3.3.Key forces shaping North America liver disease treatment industry/market
3.4.Top player positioning, 2019
3.5.Market dynamics
  3.5.1.Drivers
    3.5.1.1.Rise in consumption of alcoholic beverages and use of illegal drugs
    3.5.1.2.Surge in prevalence of liver diseases
    3.5.1.3.Rise in geriatric population
    3.5.1.4.Increase in government and non-government awareness programs
  3.5.2.Restraints
    3.5.2.1.Stringent regulatory approvals related to liver disease treatment drugs and vaccines
    3.5.2.2.Resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C
  3.5.3.Opportunity
    3.5.3.1.Presence of strong pipeline products
  3.5.4.Impact Analyses
3.6.COVID-19 Impact Analysis on North America Liver Disease Treatment Market

CHAPTER 4: NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE

4.1.Overview
  4.1.1.Market size and forecast
4.2.Antiviral Drugs
  4.2.1.Key market trends, growth factors, and opportunities
  4.2.2.Market size and forecast, by country
4.3.Immunosuppressants
  4.3.1.Key market trends, growth factors, and opportunities
  4.3.2.Market size and forecast, by country
4.4.Vaccines
  4.4.1.Key market trends, growth factors, and opportunities
  4.4.2.Market size and forecast, by country
4.5.Immunoglobulins
  4.5.1.Key market trends, growth factors, and opportunities
  4.5.2.Market size and forecast, by country
4.6.Corticosteroids
  4.6.1.Key market trends, growth factors, and opportunities
  4.6.2.Market size and forecast, by country
4.7.Targeted Therapy
  4.7.1.Key market trends, growth factors, and opportunities
  4.7.2.Market size and forecast, by country
4.8.Chemotherapy
  4.8.1.Key market trends, growth factors, and opportunities
  4.8.2.Market size and forecast, by country

CHAPTER 5: NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE

5.1.Overview
  5.1.1.Market size and forecast
5.2.Hepatitis
  5.2.1.Market size and forecast, by country
5.3.Autoimmune Diseases
  5.3.1.Market size and forecast, by country
5.4.Non-Alcoholic Fatty Liver Disease (NAFLD)
  5.4.1.Market size and forecast, by country
5.5.Cancer
  5.5.1.Market size and forecast, by country
5.6.Genetic Disorders
  5.6.1.Market size and forecast, by country
5.7.Others
  5.7.1.Market size and forecast, by country

CHAPTER 6: NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY

6.1.Overview
  6.1.1.Market size and forecast
6.2.U.S.
  6.2.1.Market share & forecast, by treatment type
  6.2.2.Market share & forecast, by disease type
6.3.Canada
  6.3.1.Market share & forecast, by treatment type
  6.3.2.Market share & forecast, by disease type
6.4.Mexico
  6.4.1.Market share & forecast, by treatment type
  6.4.2.Market share & forecast, by disease type

CHAPTER 7: COMPANY PROFILES

7.1.ABBVIE INC.
  7.1.1.Company overview
  7.1.2.Company snapshot
  7.1.3.Operating business segments
  7.1.4.Product portfolio
  7.1.5.Business performance
  7.1.6.Key strategic moves and developments
7.2.ASTELLAS PHARMA INC.
  7.2.1.Company overview
  7.2.2.Company snapshot
  7.2.3.Operating business segments
  7.2.4.Product portfolio
  7.2.5.Business performance
7.3.BRISTOL-MYERS SQUIBB COMPANY
  7.3.1.Company overview
  7.3.2.Company snapshot
  7.3.3.Operating business segments
  7.3.4.Product portfolio
  7.3.5.Business performance
  7.3.6.Key strategic moves and developments
7.4.DYNAVAX TECHNOLOGIES CORPORATION
  7.4.1.Company overview
  7.4.2.Company snapshot
  7.4.3.Operating business segments
  7.4.4.Product portfolio
  7.4.5.Business performance
  7.4.6.Key strategic moves and developments
7.5.ELI LILY AND COMPANY
  7.5.1.Company overview
  7.5.2.Company snapshot
  7.5.3.Operating business segments
  7.5.4.Product portfolio
  7.5.5.Business performance
  7.5.6.Key strategic moves and developments
7.6.EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
  7.6.1.Company overview
  7.6.2.Company snapshot
  7.6.3.Operating business segments
  7.6.4.Product portfolio
  7.6.5.Business performance
7.7.GILEAD SCIENCES, INC.
  7.7.1.Company overview
  7.7.2.Company snapshot
  7.7.3.Operating business segments
  7.7.4.Product portfolio
  7.7.5.Business performance
  7.7.6.Key strategic moves and developments
7.8.MERCK & CO. INC.
  7.8.1.Company overview
  7.8.2.Company snapshot
  7.8.3.Operating business segments
  7.8.4.Product portfolio
  7.8.5.Business performance
  7.8.6.Key strategic moves and developments
7.9.MYLAN N.V.
  7.9.1.Company overview
  7.9.2.Company snapshot
  7.9.3.Operating business segments
  7.9.4.Product portfolio
  7.9.5.Business performance
7.10.PFIZER INC. (PHARMACIA CORPORATION)
  7.10.1.Company overview
  7.10.2.Company snapshot
  7.10.3.Operating business segments
  7.10.4.Product portfolio
  7.10.5.Business performance
  7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 02.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR ANTIVIRAL, BY COUNTRY 2019–2027($MILLION)
TABLE 03.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 04.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR VACCINES TYPE, BY COUNTRY 2019–2027 ($MILLION)
TABLE 05.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR IMMUNOGLOBULINS, BY COUNTRY 2019–2027 ($MILLION)
TABLE 06.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY 2019–2027 ($MILLION)
TABLE 07.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY 2019–2027 ($MILLION)
TABLE 08.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR CHEMOTHERPAY, BY COUNTRY 2019–2027($MILLION)
TABLE 09.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2019-2027 ($MILLION)
TABLE 10.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY REGION 2019–2027($MILLION)
TABLE 11.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY REGION 2019–2027 ($MILLION)
TABLE 12.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION 2019–2027 ($MILLION)
TABLE 13.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR CANCER, BY REGION 2019–2027($MILLION)
TABLE 14.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR GENETIC DIOSRDERS, BY REGION 2019–2027 ($MILLION)
TABLE 15.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)
TABLE 16.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 17.U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 18.U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 19.CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 20.CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 21.MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 22.MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 23.ABBVIE: COMPANY SNAPSHOT
TABLE 24.ABBVIE: OPERATING SEGMENTS
TABLE 25.ABBVIE: PRODUCT PORTFOLIO
TABLE 26.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 27.ASTELLAS: COMPANY SNAPSHOT
TABLE 28.ASTELLAS: OPERATING SEGMENTS
TABLE 29.ASTELLAS: PRODUCT PORTFOLIO
TABLE 30.BMS: COMPANY SNAPSHOT
TABLE 31.BMS: PRODUCT PORTFOLIO
TABLE 32.BMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 33.DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 34.DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 35.DYNAVAX TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 36.ELI LILLY: COMPANY SNAPSHOT
TABLE 37.LILLY: OPERATING SEGMENTS
TABLE 38.ELI LILLY: PRODUCT PORTFOLIO
TABLE 39.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 40.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
TABLE 41.EMERGENT SOLUTIONS: OPERATING SEGMENTS
TABLE 42.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
TABLE 43.GILEAD: COMPANY SNAPSHOT
TABLE 44.GILEAD: OERATING SEGMENT
TABLE 45.GILEAD: PRODUCT PORTFOLIO
TABLE 46.MERCK: COMPANY SNAPSHOT
TABLE 47.MERCK: OPERATING SEGMENTS
TABLE 48.MERCK: PRODUCT PORTFOLIO
TABLE 49.MYLAN: COMPANY SNAPSHOT
TABLE 50.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 51.MYLAN: PRODUCT PORTFOLIO
TABLE 52.PFIZER: COMPANY SNAPSHOT
TABLE 53.PFIZER: OERATING SEGMENT
TABLE 54.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.NORTH AMERICA LIVER DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES (2017–2019)
FIGURE 03.TOP WINNING STRATEGIES:%AGE DISTRIBUTION, (2017–2019)
FIGURE 04.DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 05.TOP INVESTMENT POCKETS
FIGURE 06.LOW BARGAINING POWER OF SUPPLIER
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH INTENSITY OF RIVALRY
FIGURE 10.LOW THREAT OF NEW ENTRANT
FIGURE 11.TOP PLAYER POSITIONING, 2019
FIGURE 12.IMPACT ANALYSIS, NORTH AMERICA LIVER DISEASE TREATMENT MARKET
FIGURE 13.ABBVIE: NET SALES, 2017–2019 ($MILLION)
FIGURE 14.ABBVIE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 15.ABBVIE: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 16.ASTELLAS: NET SALES, 2017–2019 ($MILLION)
FIGURE 17.ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 18.ASTELLAS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 19.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 21.DYNAVAX TECHNOLOGIES: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 23.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 24.EMERGENT SOLUTIONS: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.EMERGENT SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.EMERGENT SOLUTIONS: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 27.GILEAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.MERCK: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 30.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 33.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)



More Publications